Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies. 

Eureka Therapeutics, headquartered in the San Francisco Bay Area, leverages its proprietary ARTEMIS^® cell receptor and E‑ALPHA^® antibody discovery platforms to drive innovation in safer, more effective T‑cell therapies. Through this collaboration, the two parties aim to accelerate Eureka's global clinical development by capitalizing on Porton Advanced's world-class cell and gene therapy manufacturing capabilities at their GMP sites.

Oliver Ju, Chairman of Porton Advanced, commented: "We are delighted to establish our partnership with Eureka. The seamless completion of the initial part of our collaboration program underscores our team's operational excellence and commitment to quality. Our continued collaboration will leverage our flexible models and state‑of‑the‑art manufacturing capabilities to expedite the development of groundbreaking advanced therapies."

Dr. Cheng Liu, Founder and CEO of Eureka Therapeutics, stated: "We are confident that through close collaboration with Porton Advanced, Eureka is well-positioned to accelerate our key pipeline programs, supported by Porton's robust and reliable manufacturing capabilities."

Accelerating Advanced Therapy Pipeline Development

Following the successful technology establishment, Porton Advanced will continue to support Eureka's Investigator-Initiated Trials (IITs) by providing CAR-T manufacturing services that adhere to stringent quality standards. These studies, supported by Porton Advanced's end-to-end CDMO platform, are designed to generate critical data for subsequent clinical milestones to further advance Eureka's innovative T-cell therapies.

Porton Advanced: Enabling Global Innovations in Advanced Therapies

Porton Advanced's proven process development capabilities, GMP-compliant facilities (meeting US, EU, and China standards), and extensive project experience position it as a strategic partner for international biotech companies seeking clinical and commercial CDMOs. This collaboration further validates Porton Advanced's unique value in facilitating global advanced therapy pipelines.

Porton Advanced has an extensive track record, cumulatively supporting over 60 ATMP Clinical, IND, and IIT projects in China, with orders exceeding 140 IIT batches and maintaining a flawless release success rate for all completed batches. This record highlights the company's consistent capability to meet high-quality manufacturing standards.

Porton Advanced will use all the resources, experience, and skills at the company's disposal to ensure the success of Porton Advanced's collaboration with Eureka.